UBS Group AG (USA) reaffirmed their buy rating on shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) in a research note issued to investors on Tuesday, www.tipranks.com reports. UBS Group AG (USA) currently has a $57.00 target price on the life sciences company’s stock.

A number of other equities analysts have also recently weighed in on IART. Wells Fargo & Company cut Integra LifeSciences Holdings Corporation from an outperform rating to a market perform rating in a report on Sunday, October 29th. Jefferies Group LLC reaffirmed a buy rating and issued a $56.00 price target on shares of Integra LifeSciences Holdings Corporation in a report on Sunday, October 29th. TheStreet cut Integra LifeSciences Holdings Corporation from a b rating to a c+ rating in a report on Thursday, October 26th. J P Morgan Chase & Co cut Integra LifeSciences Holdings Corporation from an overweight rating to a neutral rating and set a $44.00 price target for the company. in a report on Friday, October 27th. Finally, Oppenheimer Holdings, Inc. reaffirmed a buy rating on shares of Integra LifeSciences Holdings Corporation in a report on Thursday, October 26th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Integra LifeSciences Holdings Corporation presently has an average rating of Buy and a consensus target price of $53.64.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded up $1.83 during trading hours on Tuesday, hitting $48.05. The company had a trading volume of 749,343 shares, compared to its average volume of 815,008. The stock has a market cap of $3.78 billion, a PE ratio of 26.64, a PEG ratio of 2.11 and a beta of 0.64. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last issued its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.47 by ($0.02). The company had revenue of $278.83 million during the quarter, compared to analyst estimates of $286.00 million. Integra LifeSciences Holdings Corporation had a net margin of 4.52% and a return on equity of 16.35%. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period last year, the firm earned $0.93 EPS. equities analysts forecast that Integra LifeSciences Holdings Corporation will post 1.85 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Integra LifeSciences Holdings Corporation (IART) Earns “Buy” Rating from UBS Group AG (USA)” was posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/integra-lifesciences-holdings-corporation-iart-earns-buy-rating-from-ubs-group-ag-usa/1676851.html.

In other news, Director Barbara B. Hill bought 10,768 shares of Integra LifeSciences Holdings Corporation stock in a transaction on Tuesday, October 31st. The stock was acquired at an average price of $46.66 per share, with a total value of $502,434.88. Following the completion of the acquisition, the director now directly owns 55,540 shares of the company’s stock, valued at $2,591,496.40. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 21.50% of the stock is owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the business. FMR LLC raised its holdings in shares of Integra LifeSciences Holdings Corporation by 6.2% during the second quarter. FMR LLC now owns 8,084,562 shares of the life sciences company’s stock valued at $440,690,000 after acquiring an additional 468,678 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Integra LifeSciences Holdings Corporation by 307,726.8% during the first quarter. BlackRock Inc. now owns 7,455,564 shares of the life sciences company’s stock valued at $314,104,000 after acquiring an additional 7,453,142 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Integra LifeSciences Holdings Corporation by 116.7% during the first quarter. Vanguard Group Inc. now owns 5,656,048 shares of the life sciences company’s stock valued at $238,289,000 after acquiring an additional 3,046,488 shares during the last quarter. Capital Research Global Investors raised its holdings in shares of Integra LifeSciences Holdings Corporation by 227.0% during the second quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock valued at $212,441,000 after acquiring an additional 2,705,488 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new position in shares of Integra LifeSciences Holdings Corporation during the second quarter valued at approximately $112,068,000. 84.88% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.